Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-Q - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
NEWARK, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2025 with the following results: Sales of $48.6 million increased 13.0% from $43.0 million for the second quarter of 2024; excluding Electrochem, sales of $39.3 million declined 8.7% due to a 57.2% decrease in Communications Systems salesGross profit of $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the second quarter of 2024Operating income of $2.3 million, including one-time non-recurring costs and purchase accounting adjustments of $0.3 million, compared to $3.9 million for the second quarter of 202
NEWARK, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2025 before the market opens on Thursday, August 7, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at Noon ET on August 7, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BIbda86e3ea7b342b6944287e49c2d3e9c. Th
NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Communications Systems salesGross profit of $12.7 million, or 25.1% of revenue, compared to $11.5 million, or 27.4% of revenue, for the 2024 first quarterOperating income of $3.4 million, including one-time non-recurring costs and purchase accounting adjustments of $0.4 million, compared to $4.1 million for the 2024 first quarterGAAP EPS of $0.11 comp
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
Benchmark initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife's products and solutions meet the evolving needs of our customers. Jeff brings over two
NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation ("Ultralife" or the "Company") (NASDAQ:ULBI) has appointed Michael E. Manna as the Company's President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec will remain with Ultralife as an employee for a sixty-day period ending January 20, 2023 in an advisory role to ensure a smooth leadership transition. In addition to his new role, Mike Manna will retain his leadership position for the Company's Battery & Energy Products segment which he held prior to his appointment as President & CEO. "Over the past twe
NEWARK, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2025 with the following results: Sales of $48.6 million increased 13.0% from $43.0 million for the second quarter of 2024; excluding Electrochem, sales of $39.3 million declined 8.7% due to a 57.2% decrease in Communications Systems salesGross profit of $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the second quarter of 2024Operating income of $2.3 million, including one-time non-recurring costs and purchase accounting adjustments of $0.3 million, compared to $3.9 million for the second quarter of 202
NEWARK, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2025 before the market opens on Thursday, August 7, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at Noon ET on August 7, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BIbda86e3ea7b342b6944287e49c2d3e9c. Th
NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Communications Systems salesGross profit of $12.7 million, or 25.1% of revenue, compared to $11.5 million, or 27.4% of revenue, for the 2024 first quarterOperating income of $3.4 million, including one-time non-recurring costs and purchase accounting adjustments of $0.4 million, compared to $4.1 million for the 2024 first quarterGAAP EPS of $0.11 comp
SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)